To validate CAR-T–associated CRS, IL-2Ra KO mice were treated with either anti–IL-6R monoclonal antibody (mAb) or anti–IFN-γ mAb, which are equivalents for Tocilizumab and Emapalumab, respectively. This evidence concerns the gene IFNG and congenital rubella syndrome.